PPD, Inc. (PPD)
| Market Cap | 12.76B |
| Revenue (ttm) | 4.36B |
| Net Income (ttm) | 53.83M |
| Shares Out | 348.67M |
| EPS (ttm) | 0.16 |
| PE Ratio | 222.56 |
| Forward PE | 27.10 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $36.50 |
| Previous Close | $35.94 |
| Change ($) | 0.56 |
| Change (%) | 1.56% |
| Day's Open | 35.78 |
| Day's Range | 35.41 - 36.56 |
| Day's Volume | 524,952 |
| 52-Week Range | 14.00 - 37.00 |
PPD, Inc. (PPD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
The year has seen more than 370 companies go public, so finding the 10 best IPOs to invest in won't be easy. Here are the top contenders.
Most experienced investors are well aware of the major indexes that compose the equity markets.
PPD, Inc. (PPD) CEO David Simmons on Q3 2020 Results - Earnings Call Transcript
Investor sentiment remains strong for PPD, as shareholders have enjoyed almost 250% upside since the selloff in March. The stock has bounced away from support 7 times since then, in a narrow a...
HitGen will acquire Vernalis Limited, a Cambridge, UK CRO, from Ligand Pharmaceuticals for $25 million.
PPD saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD Announces Pricing of Secondary Offering of Shares of Common Stock
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD Announces Secondary Offering of Shares of Common Stock.
LOS ANGELES, Aug. 20, 2020 /PRNewswire/ -- Science 37, the industry leader in decentralized clinical trials, today announced it closed an oversubscribed $40 million funding round.
PPD beats the Street by $84.5 million on revenues, but misses EPS by $0.15.
PPD, Inc. (PPD) CEO David Simmons on Q2 2020 Results - Earnings Call Transcript
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq:PPD), a leading global contract research organization, today announced it has signed a new three-year agreement with Pfizer Inc. to provide...
The Renaissance IPO Index is up 37.7% year to date compared to -1.3% for the S&P 500. Here are seven new stocks to buy from this index.
PPD's (PPD) CEO David Simmons on Q1 2020 Results - Earnings Call Transcript
PPD (NASDAQ: PPD) shares are trading higher on Friday, after Morgan Stanley maintained an Overweight rating and raised its price target from $26 to $30.
PPD Inc. (NASDAQ: PPD) made an exciting entrance to the market Thursday.
PPD Inc. shares soared 14% in their trading debut Thursday, after the drug research company's initial public offering priced at the high end of its $24 to $27 price range.
About PPD
PPD provides drug development services to the biopharmaceutical industry worldwide. The company operates through Clinical Development Services and Laboratory Services segments. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri- and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central ... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Feb 6, 2020 |
| CEO David S. Simmons | Employees 25,000 |
| Stock Exchange NASDAQ | Ticker Symbol PPD |
Financial Performance
In 2019, PPD, Inc.'s revenue was $4.03 billion, an increase of 7.52% compared to the previous year's $3.75 billion. Earnings were $47.82 million, a decrease of -54.10%.
Analyst Forecasts
According to 16 analysts, the average rating for PPD, Inc. stock is "Strong Buy." The 12-month stock price forecast is 40.13, which is an increase of 9.95% from the latest price.